Shares of Integer Holdings Co. (NASDAQ:ITGR) were up 1.5% on Tuesday . The stock traded as high as $24.01 and last traded at $23.88, with a volume of 62,939 shares changing hands. The stock had previously closed at $23.52.

A number of analysts have commented on ITGR shares. Sterne Agee CRT reiterated a “buy” rating on shares of Integer Holdings in a research report on Monday, May 16th. Zacks Investment Research upgraded Integer Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th. Finally, TheStreet downgraded Integer Holdings from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $57.00.

The stock’s market capitalization is $698.26 million. The company’s 50 day moving average is $0.00 and its 200-day moving average is $0.00.

Integer Holdings (NASDAQ:ITGR) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $0.14. The company earned $348.38 million during the quarter, compared to analyst estimates of $356.72 million. During the same period in the prior year, the business posted $0.73 EPS. The company’s revenue for the quarter was up 99.2% compared to the same quarter last year. Equities analysts predict that Integer Holdings Co. will post $2.64 earnings per share for the current fiscal year.

Greatbatch, Inc is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.